-
Mashup Score: 4Online Event - 2 hour(s) ago
In vitro-transcribed mRNAs have been proven efficient in various therapeutic applications. However, manufacturing them poses challenges due in part to complexity of the molecules as well as the intricate balancing of reagents in the reaction to balance out potency and integrity. In vitro transcription (IVT) and capping reactions are not one-size-fits all, rather they must be tuned to individual molecules based on their composition, structure, and size to truly optimize mRNA development. Optimizing the
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 2Online Event - 4 hour(s) ago
Advances in the use of model systems that accurately represent human cellular development or microenvironments have led to innovations in treatments for diseases. Patient-derived organoids, self-organizing masses of cells grown from patients, allow for the investigation of molecular mechanisms of diseases such as cancer and neurodevelopmental and neurodegenerative disorders. Combining organoids with technologies such as single-cell RNA sequencing gives researchers the ability to functionally characterize
Source: www.workcast.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 15Online Event - 1 day(s) ago
Afghanistan Albania Algeria Andorra Angola Antigua and Barbuda Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Côte d’Ivoire Cabo Verde Cambodia Cameroon Canada Central African Republic Chad Chile China Colombia Comoros Congo Costa Rica Croatia Cuba Cyprus Czechia Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 11Online Event - 1 day(s) ago
Determining the critical quality attributes (CQAs) of emerging, more complex nucleic acid (NA) therapeutics and their carrier systems poses a new challenge for biopharmaceutical companies. Low molecular weight NA therapeutics, such as antisense oligonucleotides or small interfering RNA, can be fully characterized using CQAs like identity or purity using many different analytical tools. However, analyzing higher molecular weight molecules such as guide RNA, messenger RNA or plasmid therapeutics remains
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
NEW WEBINAR! On 6/6, Oliver Höcker, PhD, will discuss the advantages and limitations of current analytical techniques for determining the CQAs of NA therapeutics using examples from different NA classes. Register: https://t.co/rAWHfl5DtK #Solvias #DrugDiscovery #Bioprocessing https://t.co/sdJU68NOzO
-
-
Mashup Score: 5Online Event - 2 day(s) ago
In vitro-transcribed mRNAs have been proven efficient in various therapeutic applications. However, manufacturing them poses challenges due in part to complexity of the molecules as well as the intricate balancing of reagents in the reaction to balance out potency and integrity. In vitro transcription (IVT) and capping reactions are not one-size-fits all, rather they must be tuned to individual molecules based on their composition, structure, and size to truly optimize mRNA development. Optimizing the
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 15Online Event - 3 day(s) ago
Afghanistan Albania Algeria Andorra Angola Antigua and Barbuda Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Côte d’Ivoire Cabo Verde Cambodia Cameroon Canada Central African Republic Chad Chile China Colombia Comoros Congo Costa Rica Croatia Cuba Cyprus Czechia Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 12Online Event - 3 day(s) ago
Access to accurate and actionable information in real-time is critical for reputation management and strategic planning. In this GEN webinar, Storyful CEO Maria Pacheco will showcase several examples that illustrate how access to digital intelligence can be timely, impactful, and agile for marketing communications strategy or PR in the pharmaceutical industry. During the webinar, you’ll gain invaluable insights into leveraging data to identify patient needs, monitor competitor activity, and optimize
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 12Online Event - 5 day(s) ago
Access to accurate and actionable information in real-time is critical for reputation management and strategic planning. In this GEN webinar, Storyful CEO Maria Pacheco will showcase several examples that illustrate how access to digital intelligence can be timely, impactful, and agile for marketing communications strategy or PR in the pharmaceutical industry. During the webinar, you’ll gain invaluable insights into leveraging data to identify patient needs, monitor competitor activity, and optimize
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 10Online Event - 6 day(s) ago
About five million people in the United States alone live with traumatic brain injuries (TBIs). These injuries can quadruple the risk of developing Alzheimer’s disease, and other dementias, and increase the likelihood of developing neurodegenerative diseases such as amyotrophic lateral sclerosis. Rodent models of TBI have clarified some aspects of these injuries; however, most treatment approaches have had limited success because some of the details of the underlying mechanisms are still unclear. In this
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 11Online Event - 7 day(s) ago
While humanized animalmodels are relatively new to drug development compared to their non-humanizedcounterparts, they are critical tools in the landscape of biologic drugdevelopment. Their success is due to the ability of humanized models to developersrefine their therapies to boost efficacy and reduce toxicity which is crucialfor advancing them to the clinic. In this GEN webinar, Aaron Rose, PhD, explores how biological therapeutics are reshaping the traditional drug development process and why humanized
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
New webinar! On 5/23, Scott Alderucci will discuss ways of leveraging new technologies and experimental design for an optimized, tailored approach to mRNA therapy development. REGISTER: https://t.co/fdwJ6VHevN @CuriaCDMO #Biologics #DrugManufacturing #mRNA #Bioprocessing https://t.co/FRL7c09tIr